Standardization for Reishi extracts often hinges on a narrow set of markers. A new analysis suggests this approach may fail to verify the compounds responsible for the mushroom's sought-after cognitive and immunomodulatory effects.
Nootropics Depot CEO Paul Eftang has published a white paper, "Beyond the Marker: A Bioactives-First Standard for Reishi Quality," which critiques current industry practices. The document argues that while marker compounds can confirm ingredient identity, they are frequently treated as a proxy for overall quality. This can create a disconnect between a product's label claims and its intended biological activity.
The Marker Misalignment Problem
The core of the critique is pharmacological specificity. Reishi contains multiple classes of bioactive compounds with distinct mechanisms of action. However, commercial standardization often focuses on a subset that is either easier to measure or more familiar in the marketplace. This can lead to products standardized for identity rather than function. The paper posits that such legacy systems can persist in a category long after their original utility has been outpaced by more nuanced science.
A Proposed Bioactives-First Framework
To address this, the white paper proposes a Standardized Target Analyte Grouping (STAG) framework. STAG shifts quality assessment from isolated markers to groups of compounds that collectively reflect intended biological activity. The model calls for clearer target selection, transparent analytical methods, and specifications directly tied to an extract's active chemistry. The goal is to create more auditable, scientifically coherent standards.
Implications for Efficacy and Trust
For the performance-focused consumer, the standardization method on a supplement label is a critical data point. A bioactives-first framework, as proposed, would theoretically increase the probability that a purchased product contains the compound groups associated with desired effects—from supporting neural resilience to modulating stress response. This represents a move from trust in marketing to verification of relevant chemistry. The paper frames this as an opportunity for manufacturers and labs to elevate category-wide transparency and product integrity.